[Translation] A phase II clinical study of Maqin granules versus placebo in the treatment of post-cold cough and cough variant asthma (CVA) (wind evil invading the lungs, lung qi failure to ventilate syndrome).

1. 探索麻芩颗粒改善感冒后咳嗽症状的有效性； 2. 探索麻芩颗粒改善咳嗽变异性哮喘症状的有效性； 3. 探索麻芩颗粒改善感冒后咳嗽、咳嗽变异性哮喘（风邪犯肺、肺气失宣证）的作用； 4. 观察麻芩颗粒的安全性及不良反应。

[Translation]

1. To explore the effectiveness of Maqin Granules in improving cough symptoms after cold; 2. To explore the effectiveness of Maqin Granules in improving cough variant asthma symptoms; 3. To explore the role of Maqin Granules in improving cough after cold and cough variant asthma (wind evil invading the lungs, lung qi failure to vent syndrome); 4. To observe the safety and adverse reactions of Maqin Granules.

Start Date-

Sponsor / Collaborator

Sichuan Academy of Chinese Medicine Sciences

100 Clinical Results associated with Maqin Granules

100 Translational Medicine associated with Maqin Granules

100 Patents (Medical) associated with Maqin Granules

Literatures (Medical) associated with Maqin Granules

01 Oct 2020·Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan

Efficacy of active compounds of Chanqin granules on airway neurogenic inflammation induced by PM2.5 in vivo.

Article

Author: Shen, Ruobing ; Yu, Xiaoping ; Ju, Ya

OBJECTIVETo investigate the efficacy of active compounds of Chanqin (CQ) granules on PM2.5-induced airway neurogenic inflammation in vivo, and to elucidate the underlying mechanisms of action.METHODSThe Traditional Chinese Medicine systems pharmacology (TCMSP) database was searched, and the results were combined with oral bioavailability and drug analysis to identify the compounds in CQ granules. The pharmacophore modeling approach was used to predict the compound targets, and the diseases corresponding to the targets were obtained by searching the therapeutic target database (TTD), pharmacogenomics knowledgebase (PharmGKB) and DrugBank databases. Cytoscape software was used to construct the network pharmacological charts for Component-Target and Target-Disease interactions of the CQ granules. Then, the mechanisms of action and effectiveness of CQ granules for the treatment of PM2.5-induced airway neurogenic inflammation were analyzed.RESULTSA total of 195 compounds and 171 targets were obtained from the analyses. A total of 569 corresponding diseases were identified for these targets. Component-target and target-disease networks were constructed. The possible mechanisms and effective components in CQ granules for treating airway neurogenic inflammation were analyzed. Quercetin, kaempferol and isorhamnetin, beta-sitosterol and sitosterol, which are typically found in the formulation, have extensive pharmacological activities, including anti-inflammatory, antioxidant and antiviral actions and neuroprotective properties. Among these targets, androgen receptor, estrogen receptor, prostaglandin G/H synthase 2, and inducible nitric oxide synthase play important pathological roles, including the induction of neurogenic inflammation. CQ granules may have therapeutic effectiveness for numerous diseases in addition to respiratory diseases, including neoplasms, digestive system diseases, cardiovascular diseases, respiratory tract diseases and nervous system diseases. In vivo, CQ granules are effective in treating pulmonary inflammation and downregulate neuropeptides in the bronchoalveolar lavage fluid after PM2.5 exposure. CQ granules significantly decreased the levels of neurokinin A, neurokinin B and calcitonin gene-related peptide in the lung and dorsal root ganglia. CQ also significantly suppressed the upregulation of p-extracellular regulated protein kinase 1/2 and p-methyl ethyl ketone 1/2 induced by PM2.5 exposure.CONCLUSIONCQ granules have potential for the treatment of neurogenic inflammation induced by PM2.5 in vivo, and the mechanism might involve downregulation of neuropeptides in the BALF, lung and dorsal root ganglia.

100 Deals associated with Maqin Granules

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Common Cold	Phase 2	CN	Sichuan Academy of Chinese Medicine Sciences	12 Apr 2019
Cough	Phase 2	CN	Sichuan Academy of Chinese Medicine Sciences	12 Apr 2019
Cough variant asthma	Phase 2	CN	Sichuan Academy of Chinese Medicine Sciences	12 Apr 2019

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Maqin Granules

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation